Choosing the Right Excipient for Optimal Dosage Form Performance in Immunocompromised Patients
A research recent featured in the Journal of AIDS and HIV Research showed the potential of Low-Dose Naltrexone (LDN) in stabilizing CD4 counts among untreated HIV+ individuals and amplifying CD4 count increments when used alongside antiretroviral therapy. This breakthrough offers promising prospects for advancing HIV management strategies. Compounding of LDN capsules In the realm of … Continued
Read more